GlassScriptPhysician profile
Luis E Zarazua
NPI 1326628736
$2,126.50
in general payments reported to CMS, 2019-2025
29 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $490 · 2023: $360 · 2024: $383 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $258.27 | 2021-2025 | Repatha, Otezla |
| Lilly USA, LLC | $250.56 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $189.16 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $174.35 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $161.54 | 2021-2024 | |
| Glaxosmithkline, LLC. | $136.44 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.63 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $83.41 | 2024-2025 | Airsupra |
| Becton, Dickinson and Company | $73.25 | 2021-2022 | |
| Novo Nordisk INC | $63.84 | 2021-2025 | Wegovy |
| Exact Sciences Corporation | $63.52 | 2024-2025 | Cologuard Collection Kit |
| Organon LLC | $48.00 | 2022 | |
| Corcept Therapeutics | $46.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.34 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.26 | 2022-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $41.95 | 2025 | |
| Janssen Pharmaceuticals, INC | $41.33 | 2021-2023 | Xarelto |
| Ultragenyx Pharmaceutical INC. | $36.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.59 | 2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $29.47 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $28.90 | 2024 | Ultomiris |
| Argenx US, INC. | $27.62 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Lifescan, INC. | $25.63 | 2022 | |
| Sumitomo Pharma America, INC. | $21.80 | 2025 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $21.70 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $20.54 | 2021 | |
| Gilead Sciences, INC. | $18.04 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2024 | Austedo Xr |
| Biocryst US Sales Co., LLC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Zarazua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.